EUVIMEDEUVIMED entdecken
Crossref

Physiologically Regulated Frataxin Gene Replacement Restores Neurological Function in a Mouse Model of Friedreich Ataxia

Federica Pilotto, Laure Dall'Agnol, Laurence Reutenauer, Marie Paschaki, Hélène Puccio iD

Human Gene Therapy · 09.08.2026

DOI: 10.1177/10430342261474315 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Gene Therapy, online erschienen am 09.08.2026. Verfasst von Federica Pilotto und 4 weiteren Autor:innen. Beteiligte Einrichtung: Unversité Lyon 1, CNRS UMAR 5261, Inserm U1315, Institut NeuroMyoGène (INMG), Laboratoire Pathophysiologie du Neurone et du Muscle (PGNM), Lyon, Fran…. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Friedreich ataxia research Alliance.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Friedreich ataxia (FA) is a progressive neurodegenerative disorder caused by reduced expression of frataxin (FXN), a mitochondrial protein essential for iron-sulfur (Fe-S) cluster biogenesis. Although gene therapy strategies aimed at restoring FXN have shown promise, excessive expression can lead to mitochondrial dysfunction, emphasizing the importance of maintaining FXN within a physiological range. Here, we evaluated a gene therapy approach based on a human mini-frataxin construct (miniFXN7) incorporating an endogenous regulatory element to enable controlled FXN expression. The construct was delivered systemically using an AAV-PHP.eB vector in the Pvalb -cKO mouse model of FA. MiniFXN7 treatment resulted in widespread neuronal transduction and restoration of FXN expression toward a near-physiological range in the neuronal populations examined. Treated mice exhibited sustained improvements in motor coordination and proprioceptive function, including normalization of H-reflex responses. At the cellular level, miniFXN7 restored succinate dehydrogenase activity, a mitochondrial Fe-S enzyme, and was associated with partial normalization of mitochondrial morphology. In parallel, neuronal integrity was preserved and astrogliosis reduced across the cerebellum. These findings demonstrate that physiologically regulated FXN replacement is sufficient to achieve substantial functional rescue in FA, supporting a gene therapy strategy based on a transgene expression driven by endogenous regulatory elements.

Schlagwörter

Stichwörter der Autor:innen

Friedreich ataxiaPvalb-cKO mousegene therapyminiFXN7

Autor:innen und Institutionen

  • Unversité Lyon 1, CNRS UMAR 5261, Inserm U1315, Institut NeuroMyoGène (INMG), Laboratoire Pathophysiologie du Neurone et du Muscle (PGNM), Lyon, France.

ORCID-Profile: Hélène Puccio

Förderung

  • Friedreich ataxia research Alliance

Zitieren

APA

Pilotto, F., Dall'Agnol, L., Reutenauer, L., Paschaki, M., & Puccio, H. (2026). Physiologically Regulated Frataxin Gene Replacement Restores Neurological Function in a Mouse Model of Friedreich Ataxia. Human Gene Therapy. https://doi.org/10.1177/10430342261474315

Vancouver

Pilotto F, Dall'Agnol L, Reutenauer L, Paschaki M, Puccio H. Physiologically Regulated Frataxin Gene Replacement Restores Neurological Function in a Mouse Model of Friedreich Ataxia. Human Gene Therapy. 2026. doi:10.1177/10430342261474315

BibTeX
@article{Pilotto2026,
  author = {Pilotto, Federica and Dall'Agnol, Laure and Reutenauer, Laurence and Paschaki, Marie and Puccio, Hélène},
  title = {Physiologically Regulated Frataxin Gene Replacement Restores Neurological Function in a Mouse Model of Friedreich Ataxia},
  journal = {Human Gene Therapy},
  year = {2026},
  doi = {10.1177/10430342261474315}
}
Kostenlos starten →